Douglas Logan

1.3k total citations · 1 hit paper
15 papers, 992 citations indexed

About

Douglas Logan is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Douglas Logan has authored 15 papers receiving a total of 992 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 7 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Douglas Logan's work include Lipoproteins and Cardiovascular Health (7 papers), Diabetes Treatment and Management (5 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Douglas Logan is often cited by papers focused on Lipoproteins and Cardiovascular Health (7 papers), Diabetes Treatment and Management (5 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Douglas Logan collaborates with scholars based in United States and Canada. Douglas Logan's co-authors include Neil Stahl, Evan A. Stein, Richard Wu, Eleanor Lisbon, Yunling Du, María J. Gutiérrez, George D. Yancopoulos, Gary D. Swergold, Scott Mellis and William Smith and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Douglas Logan

15 papers receiving 964 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

2012 505 citations Evan A. Stein, Scott Mellis et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas Logan United States	9	626	324	252	137	131	15	992
Therèse Heinonen Canada	19	691 1.1×	334 1.0×	221 0.9×	96 0.7×	242 1.8×	39	1.2k
Carmen H. Tong United States	15	323 0.5×	236 0.7×	119 0.5×	37 0.3×	183 1.4×	32	1.1k
Robert M. Stoekenbroek Netherlands	22	900 1.4×	229 0.7×	371 1.5×	218 1.6×	226 1.7×	43	1.3k
Gissette Reyes‐Soffer United States	18	672 1.1×	406 1.3×	369 1.5×	64 0.5×	156 1.2×	38	1.1k
M van Linde-Sibenius Trip Netherlands	8	706 1.1×	401 1.2×	480 1.9×	122 0.9×	116 0.9×	8	1.2k
Daniel M. Kolansky United States	10	493 0.8×	258 0.8×	179 0.7×	36 0.3×	130 1.0×	17	835
Hal Kennedy United States	17	886 1.4×	290 0.9×	613 2.4×	49 0.4×	156 1.2×	21	1.3k
Ariel Brautbar United States	16	461 0.7×	273 0.8×	206 0.8×	36 0.3×	278 2.1×	39	1.0k
М. В. Ежов Russia	17	1.3k 2.1×	648 2.0×	431 1.7×	211 1.5×	152 1.2×	154	1.8k
Michael A. Lauer United States	12	1.2k 1.9×	500 1.5×	738 2.9×	36 0.3×	284 2.2×	18	1.8k

Countries citing papers authored by Douglas Logan

Since Specialization

Citations

This map shows the geographic impact of Douglas Logan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Logan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Logan more than expected).

Fields of papers citing papers by Douglas Logan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Logan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Logan. The network helps show where Douglas Logan may publish in the future.

Co-authorship network of co-authors of Douglas Logan

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Logan. A scholar is included among the top collaborators of Douglas Logan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Logan. Douglas Logan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Bhatt, Deepak L., Tilo Großer, Jing-fei Dong, et al.. (2017). Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. Journal of the American College of Cardiology. 69(6). 603–612. 106 indexed citations

Vajda, Eric G., Douglas Logan, Kenneth C. Lasseter, et al.. (2016). Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 19(1). 24–32. 41 indexed citations

Donovan, Joanne M., Richard L. Dunbar, Douglas Logan, et al.. (2014). PHASE 1 SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF CAT-2003, A NOVEL ACTIVATOR OF LIPOPROTEIN LIPASE, DEMONSTRATES REDUCTIONS IN POSTPRANDIAL TRIGLYCERIDES. Journal of the American College of Cardiology. 63(12). A1450–A1450. 6 indexed citations

Henry, Robert R., Julio Rosenstock, Douglas Logan, et al.. (2014). Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. Journal of Diabetes and its Complications. 28(3). 393–398. 61 indexed citations

Donovan, Joanne M., Richard L. Dunbar, Douglas Logan, et al.. (2014). Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Decreases Postprandial Triglycerides†. Journal of clinical lipidology. 8(3). 311–311. 1 indexed citations

Henry, Robert R., Douglas Logan, Thomas R. Alessi, & Michelle A. Baron. (2013). A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes☆☆This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.. Clinical Therapeutics. 35(5). 634–645.e1. 18 indexed citations

Gurbel, Paul A., Kevin P. Bliden, Douglas Logan, et al.. (2013). The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel. Journal of the American College of Cardiology. 62(6). 505–512. 107 indexed citations

Henry, Robert R., Julio Rosenstock, Douglas Logan, et al.. (2013). Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care. 36(9). 2559–2565. 32 indexed citations

Stein, Evan A., Scott Mellis, George D. Yancopoulos, et al.. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. Obstetrical & Gynecological Survey. 67(7). 413–414. 10 indexed citations

10.

Price, Matthew J., Brian Baker, Darell Heiselman, et al.. (2012). Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease. Journal of the American College of Cardiology. 59(25). 2338–2343. 84 indexed citations

11.

Stein, Evan A., Scott Mellis, George D. Yancopoulos, et al.. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. New England Journal of Medicine. 366(12). 1108–1118. 505 indexed citations breakdown →

12.

Gurbel, Paul A., Kevin P. Bliden, Douglas Logan, et al.. (2012). TCT-54 The Influence of Smoking Status On The Pharmacodynamics of Prasugrel and Clopidogrel:The PARADOX Study. Journal of the American College of Cardiology. 60(17). B17–B17. 3 indexed citations

13.

Swergold, Gary D., W. Smith, Scott Mellis, et al.. (2011). Abstract 16265: Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 With a Monoclonal Antibody REGN727/SAR236553, Effectively Reduces Low-Density-Lipoprotein Cholesterol, as Mono or Add-on Therapy in Heterozygous Familial and Non Familial Hypercholesterolemia. Circulation. 124. 6 indexed citations

14.

Price, Matthew J., Douglas Logan, Brian Baker, et al.. (2011). RECOVERY OF PLATELET FUNCTION FOLLOWING DISCONTINUATION OF PRASUGREL OR CLOPIDOGREL MAINTENANCE DOSING IN ASPIRIN-TREATED SUBJECTS WITH STABLE CORONARY DISEASE: THE RECOVERY TRIAL. Journal of the American College of Cardiology. 57(14). E1636–E1636. 5 indexed citations

15.

Young, G. Bryan, et al.. (1986). The role of myo-inositol in multiple sclerosis.. Journal of Neurology Neurosurgery & Psychiatry. 49(3). 265–272. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact